EMERGENT BIOSOLUTIONS INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
EMERGENT BIOSOLUTIONS INC. (EBS) had Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued of $800.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Balance Sheet › Liabilities
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued · last filed 2026-02-27
- 2025-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $800.00K.
- 2024-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $800.00K.
- 2023-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $1.60M.
- 2022-12-31: Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $1.60M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued |
|---|---|
| 2025-12-31 | $800.00K 10-K · filed 2026-02-27 |
| 2024-12-31 | $800.00K 10-K · filed 2026-02-27 |
| 2023-12-31 | $1.60M 10-K · filed 2025-03-04 |
| 2022-12-31 | $1.60M 10-K · filed 2024-03-08 |
| 2021-12-31 | $3.70M 10-K/A · filed 2023-12-11 |
| 2014-12-31 | $26.00K 10-K · filed 2015-03-09 |
| 2013-12-31 | $15.00K 10-K · filed 2015-03-09 |
| 2012-12-31 | $25.00K 10-K · filed 2014-03-10 |
| 2011-12-31 | $26.00K 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |